CapsoVision (CV) Stock Price, News & Analysis

Company Overview

CapsoVision, Inc. (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting. This platform integrates seamlessly with the CapsoCam capsule, allowing physicians to access endoscopy images and diagnostic reports remotely and collaborate more efficiently on case reviews. The combination of the CapsoCam Plus capsule and the CapsoCloud platform supports a patient-centric workflow and can help reduce turnaround times for gastroenterology practices.

Founded on principles of innovation in gastrointestinal imaging, CapsoVision operates from its headquarters in Rochester, Minnesota, and serves a broad customer base across the United States and select international markets through a network of direct sales representatives and distribution partners. Its products have obtained regulatory clearances in multiple regions, and the company continues to invest in clinical research and new product development aimed at enhancing patient comfort and diagnostic accuracy.

CapsoVision is led by a management team with deep expertise in medical device commercialization and gastroenterology products. Under their guidance, the company focuses on expanding its market presence, advancing regulatory approvals, and fostering strategic collaborations with healthcare providers to support adoption of capsule endoscopy as a minimally invasive alternative to traditional endoscopic procedures.

Key Stats

• Today's Range: $3.60 to $4.29
• 50-Day Range: $3.56 to $4.76
• 52-Week Range: $3.43 to $5.72
• Volume: 49,871 shs
• Average Volume: 26,207 shs
• Market Capitalization: $192.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Strong Buy

CV Stock Analysis - Frequently Asked Questions

How have CV shares performed this year?

CapsoVision's stock was trading at $4.57 on January 1st, 2025. Since then, CV shares have decreased by 9.8% and is now trading at $4.12.

How were CapsoVision's earnings last quarter?

CapsoVision, Inc. (NASDAQ:CV) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $1.91. The business earned $3.32 million during the quarter, compared to analysts' expectations of $3.20 million.

When did CapsoVision IPO?

CapsoVision (CV) raised $28 million in an initial public offering on Wednesday, July 2nd 2025. The company issued 5,300,000 shares at a price of $5.00-$5.50 per share. The Benchmark Company and Roth Capital Partners acted as the underwriters for the IPO.

When did the company's quiet period expire?

CapsoVision's quiet period expired on Monday, August 11th. CapsoVision had issued 5,500,000 shares in its public offering on July 2nd. The total size of the offering was $27,500,000 based on an initial share price of $5.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of CapsoVision?

Shares of CV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CV
• CIK: 1378325
• Web: N/A
• Phone: (408) 370-4790
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CapsoVision: $5.50
• High Price Target: $6.00
• Low Price Target: $5.00
• Potential Upside/Downside: +33.5%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $12.52 million
• Price / Sales: 15.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 46,774,000
• Free Float: N/A
• Market Cap: $192.71 million
• Optionable: N/A
• Beta: N/A